DLDominic Lenz

Dominic Lenz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dominic Lenz has a total of 365 co-authors. Here are the top co-authors by number of shared publications:

  • Georg F. Hoffmann

    Division of Paediatric Neurology and Metabolic Medicine Heidelberg University Medical Faculty Heidelberg, Centre for Paediatric and Adolescent Medicine Heidelberg Germany

    12 shared publications
  • Christian Staufner

    Heidelberg University, Medical Faculty Heidelberg, Center for Pediatric and Adolescent Medicine 2 , Department I, Division of Pediatric Neurology and Metabolic Medicine, 69120 Heidelberg

    11 shared publications
  • Stefan Kölker

    Division of Paediatric Neurology and Metabolic Medicine Heidelberg University Medical Faculty Heidelberg, Centre for Paediatric and Adolescent Medicine Heidelberg Germany

    9 shared publications
  • Christian Staufner

    Division of Paediatric Neurology and Metabolic Medicine Heidelberg University Medical Faculty Heidelberg, Centre for Paediatric and Adolescent Medicine Heidelberg Germany

    8 shared publications
  • Holger Prokisch

    Institute of Neurogenomics, Helmholtz Center Munich, Munich, Germany; Institute of Human Genetics, TUM School of Medicine and health, Technical University of Munich, Munich, Germany

    8 shared publications
  • Alexander Fichtner

    Division of Paediatric Neurology and Metabolic Medicine Heidelberg University Medical Faculty Heidelberg, Centre for Paediatric and Adolescent Medicine Heidelberg Germany

    6 shared publications

Latest Publications

  • Open Access

    Pathomechanism of Fever‐Induced Liver Failure in NBAS Deficiency and Treatment Effect of NAC —Observations In Vitro and In Vivo

    by Tian Sun, Nicole Hammann, Lina Leghlam, Bianca Peters, Cigdem Arikan, Sarah M. Bedoyan, Qian Chen, Tal Dattner, Felix Distelmaier, Alexander Fichtner, et al.

    Background and Aims: Pathogenic variants in neuroblastoma amplified sequence ( NBAS ) gene causes infantile liver failure type 2 (IFLS2; MIM 616483), characterised by recurrent episodes of liver failure triggered by febrile infections. The underlying pathophysiological mechanisms remain incompletely understood. With this work we try to shed light on the pathomechanism and propose a potential therapeutic option. Methods: For in vitro analyses, human skin fibroblasts were obtained from three individuals with ILFS2 and one healthy control. Cells were cultivated at 37°C or 40°C. Western blots were performed to assess NBAS protein and its interaction partners. Furthermore, immunofluorescence and electron microscopy were used to examine morphological changes associated with endoplasmic reticulum (ER) stress. Apoptosis was measured using flow cytometry. The effects of N ‐acetylcysteine (NAC) treatment were analysed not only in cultured fibroblasts but also in vivo retrospectively in 16 affected individuals. Results: We demonstrate that elevated temperature induces ER stress in fibroblasts from individuals with NBAS variants, leading to increased reactive oxygen species (ROS) production and apoptosis. Treatment with the antioxidant NAC, an established therapeutic in acetaminophen‐induced liver failure, effectively mitigated oxidative stress and reduced apoptosis in vitro. In a retrospective clinical analysis, there was a trend that NAC treatment was associated with reduced severity of hepatic crises, suggesting a potential therapeutic benefit. Conclusions: Our findings link fever‐induced ER stress, ROS accumulation, and apoptosis to the pathogenesis of liver failure in NBAS deficiency. NAC attenuates these cellular stress responses and may represent a promising supportive treatment option in NBAS‐associated liver failure.


  • Open Access

    Transaldolase deficiency – natural disease course towards adulthood

    by Viktoria Bea Horvath, Konstantinos Tsiakas, Heiko Brennenstuhl, Daniela Choukair, Nicole Hammann, Moritz Niesert, Alexander Fichtner, Holger Prokisch, René Santer, Matias Wagner, et al.


  • Open Access

    SCYL1 deficiency in CALFAN syndrome is associated with ER stress and cell death

    by John Hellicar, Tal Dattner, Tian Sun, Lily Percival, Ruby Chrisp, Andrea Pietrobattista, Tomasz Witkos, Aleksander Mironov, Lina Leghlam, Carolin Jentsch, et al.

    CALFAN syndrome is a rare genetic disorder affecting the nervous system and liver, with skeletal abnormalities also reported. It is caused by mutations in SCYL1, a gene encoding a ubiquitously expressed protein localized to the secretory pathway. SCYL1 interacts with trafficking components, including ARF GTPases and the COPI vesicle coat complex, and appears to function in retrograde secretory trafficking. Despite this knowledge, the mechanisms that underlie CALFAN pathology remain poorly understood. Here, using fibroblasts obtained from patients diagnosed with CALFAN syndrome and from SCYL1 knockout fibroblasts, we reveal an accumulation of the abundant secretory cargo procollagen type I in the endoplasmic reticulum (ER) upon SCYL1 deficiency. Surprisingly, we failed to observe procollagen-I-trafficking defects in the SCYL1-deficient cells. Nevertheless, ER accumulation of procollagen-I correlated with ER distension and induction of ER stress in the patient fibroblasts, which also underwent increased cell death. The phenotypes were observed at elevated temperatures, mimicking the induction of pathology under febrile conditions in patients with CALFAN syndrome. Our data suggest that ER stress induction is a pathological mechanism in CALFAN syndrome and that targeting this process may represent a therapeutic strategy.


  • Open Access

    Paediatric acute liver failure: A prospective, nationwide, population‐based surveillance study in Germany

    by Dominic Lenz, Muhammad Abdulaziz, Bianca Peters, Matias Wagner, Lea D. Schlieben, Victor M. Corman, Ulrich Baumann, Philip Bufler, Tal Dattner, Rainer Ganschow, et al.

    Objectives: Paediatric acute liver failure (PALF) is a rare but life‐threatening condition, yet comprehensive epidemiological data in Germany are lacking. Our study aimed to systematically analyse incidence, aetiology, and outcome of PALF in Germany. Methods: In a nationwide, population‐based surveillance study, cases of PALF (defined following the PALF study group inclusion criteria) were queried from 2016 to 2018 through the German Paediatric Surveillance Unit (ESPED). Demographic, clinical, laboratory, therapeutic, and outcome data were collected and analysed. In case of unexplained aetiology, whole exome and virus sequencing was offered as a complementary diagnostic. Results: Over the 3‐year period, 148 cases were reported, yielding an estimated incidence of 3.7 per 1 million children per year. Neonates and infants were predominantly affected (45% of the cases); median age at PALF was 1.2 years (range: 0–17.9 years). Metabolic/genetic diseases were the most common cause (23%), followed by infectious causes (17%). The overall diagnostic yield was 73%, diagnosis remained unknown in 40 cases. Clinical outcome was age‐dependent: new‐borns showed a significant higher lethality (42%), followed by infants (29%), toddlers (15%), and school children (12%). Liver transplantation was reported in 22% of cases. Conclusions: This study provides comprehensive insights into PALF epidemiology in Germany. Metabolic/genetic causes and infectious diseases were most common. Advances in standardised diagnostic work‐up and genetic analysis have enhanced diagnostic yield, yet mortality remains substantial, particularly among neonates. Further research is warranted to improve diagnostic accuracy, therapeutic outcomes, and overall management of PALF.


  • Open Access

    Hepatic Phenotype in NBAS‐Associated Disease: Clinical Course, Prognostic Factors and Outcome in 230 Patients

    by Bianca Peters, Lea Dewi Schlieben, Heiko Brennenstuhl, Cigdem Arikan, Sarah M. Bedoyan, Fatma Derya Bulut, Ellen Crushell, Carlo Dionisi‐Vici, Ada Drab, Alexander Fichtner, et al.

    Background and Aims: Since described in 2015, NBAS‐associated disease has emerged as an important cause of acute liver failure (ALF) in children. We analysed the variable expression, genotype–phenotype association, outcome and prognostic factors of the hepatic involvement. Methods: Individuals with biallelic pathogenic NBAS variants were recruited within an international observational study, including new and previously published patients. Results: We studied 230 individuals, including 13 previously unreported patients. The liver was the most frequently affected organ (63.4%), with 41.3% experiencing at least one ALF. The median age at onset was 0.9 years, the median age at last ALF 5 years, the latest ALF occurred at 24 years. Liver crises were triggered by febrile infections and presented with highly increased hepatic transaminases. Liver involvement varied significantly between the subgroups: 91.7% of patients with infantile liver failure syndrome type 2 and 88.9% of patients from the combined subgroup (variants affecting β‐propeller domain) presented with ALF, whereas SOPH (stature, optic atrophy, Pelger–Huët anomaly) patients mostly had either no liver involvement (66.4%) or persistently elevated transaminases without ALF (28%). The rate of native liver survival was 83.9%; 16 individuals underwent liver transplantation and 24 died. Conclusion: Liver abnormalities are common and the leading cause of death in NBAS‐associated disease. There is a clear genotype–phenotype association regarding the hepatic involvement. Liver crises occur primarily during infancy; however, early medical attention in case of febrile infections is necessary at all ages. Liver transplantation prevents ALF, but its risks must be weighed against the frequency and severity of liver crises decreasing with age.


  • Open Access

    Hepatic Form of Dihydrolipoamide Dehydrogenase Deficiency ( DLDD ): Phenotypic Spectrum, Laboratory Findings, and Therapeutic Approaches in 52 Patients

    by Nicole Hammann, Christian Staufner, Lea Dewi Schlieben, Antal Dezsőfi‐Gottl, René G. Feichtinger, Johannes Häberle, Norman Junge, Vassiliki Konstantopoulou, Robert Kopajtich, Valérie McLin, et al.

    Dihydrolipoamide dehydrogenase deficiency (MIM 246900/DLDD) is an autosomal recessive mitochondrial disease with three clinical subgroups. The hepatic form leads to recurrent metabolic decompensations often accompanied by elevated levels of liver transaminases (ELT) in blood, sometimes progressing to acute liver failure (ALF). Genetically, it is linked to the p.G229C variant in the DLD gene, which has been reported in the Ashkenazi Jewish and Arabic population. In this study, we analyzed phenotypic diversity, therapeutic management, and outcome in novel symptomatic individuals with hepatic DLDD identified by whole exome sequencing ( n = 7) in Central Europe as well as in previously reported cases ( n = 45). Fifty‐one of 52 DLDD patients carried the p.G229C variant (39 in a homozygous state). During decompensations, precipitated by febrile infectious disease or fasting, affected individuals presented with nausea, vomiting, abdominal pain, hepatomegaly, hypoglycemia, and lactic acidosis. In individuals homozygous for the p.G229C variant, neurologic manifestations were rare, whereas mild neurologic symptoms were found in individuals ( n = 8) carrying a different DLD variant in trans . During decompensation, levels of specific plasma amino acids like citrulline or branched‐chain amino acids, and urinary organic acids, like 2‐oxoglutaric acid, were frequently elevated. However, known biomarkers—with the exception of lactate—were not consistently elevated during these episodes and typically normal in the interval, highlighting the usefulness of early genetic testing in all children with unexplained ELT or ALF to reduce the time to diagnosis. While there exists consensus for rescue therapy with intravenous glucose during decompensations and maintenance therapy with riboflavin, therapies with thiamine and antioxidants (e.g., N‐acetylcysteine) were reported to be useful in single individuals with recurrent decompensations.


  • Open Access

    Missense variants in the TRPM7 α-kinase domain are associated with recurrent pediatric acute liver failure

    by Lea D. Schlieben, Melanie T. Achleitner, Billy Bourke, Max Diesner, René G. Feichtinger, Alexander Fichtner, Christa Flechtenmacher, Nedim Hadzic, Robert Hegarty, Andreas Heilos, et al.

    Background: Pediatric acute liver failure (PALF) is a rare and life-threatening condition. In up to 50% of PALF cases, the underlying etiology remains unknown during routine clinical testing. This lack of knowledge complicates clinical management and liver transplantation decisions. Recently, whole-exome sequencing has identified genetic disorders in a large number of cases without specific laboratory biomarkers or metabolic fingerprints. Methods: We describe how further analysis of whole-exome sequencing data combined with proteomic analyses in 5 previously unsolved PALF patients, where no pathogenic variants in genes previously associated with acute liver failure were identified, revealed rare biallelic variants in transient receptor potential cation channel subfamily M member 7 (TRPM7). Results: We establishe TRPM7 as a novel disease gene for PALF. Yet, the cation channel kinase TRPM7 has not been associated with any Mendelian disorder. No homozygous loss-of-function variants were found in in-house exomes or publicly available databases. Rare biallelic TRPM7-variants were significantly enriched in the PALF cohort compared with a pediatric control cohort. Viral infections preceded the majority of PALF episodes. Recurrent PALF episodes characterized the disease course with rapid progression, leading to early death in 3 cases. Proteomic analyses of patient fibroblasts unveiled significantly reduced TRPM7 protein levels, indicative of functional impairment. Severely reduced Mg2+ levels in one individual with a mutation in the channel domain suggests a potential interaction between disturbed Mg2+ homeostasis and PALF. The consistent presence of mutations in the TRPM7 protein-kinase-domain across all patients suggests its specific relevance in PALF. Conclusions: Our data extend the genetic spectrum of recurrent PALF and prompt consideration of TRPM7 in children with unexplained liver failure.


  • Open Access

    MRI in LARS1 deficiency—Spectrum, patterns, and correlation with acute neurological deterioration

    by Nicole Hammann, Dominic Lenz, Alyssa Bianzano, Ralf A. Husain, Eva Forman, Jonathan A. Bernstein, Tal Dattner, Marc Engelen, Andrea K. Hanson‐Kahn, Bertrand Isidor, et al.

    Leucine aminoacyl tRNA‐synthetase 1 (LARS1)‐deficiency (infantile liver failure syndrome type 1 (ILFS1)) has a multisystemic phenotype including fever‐associated acute liver failure (ALF), chronic neurologic abnormalities, and encephalopathic episodes. In order to better characterize encephalopathic episodes and MRI changes, 35 cranial MRIs from 13 individuals with LARS1 deficiency were systematically assessed and neurological phenotype was analyzed. All individuals had developmental delay and 10/13 had seizures. Encephalopathic episodes in 8/13 were typically associated with infections, presented with seizures and reduced consciousness, mostly accompanied by hepatic dysfunction, and recovery in 17/19 episodes. Encephalopathy without hepatic dysfunction occurred in one individual after liver transplantation. On MRI, 5/7 individuals with MRI during acute encephalopathy had deep gray matter and brainstem changes. Supratentorial cortex involvement (6/13) and cerebellar watershed injury (4/13) occurred with seizures and/or encephalopathy. Abnormal brainstem contour on sagittal images (8/13), atrophy (8/13), and myelination delay (8/13) were not clearly associated with encephalopathy. The pattern of deep gray matter and brainstem changes are apparently characteristic of encephalopathy in LARS1‐deficiency, differing from patterns of hepatic encephalopathy or metabolic stroke in organic acidurias and mitochondrial diseases. While the pathomechanism remains unclear, fever and energy deficit during infections might be causative; thus, sufficient glucose and protein intake along with pro‐active fever management is suggested. As severe episodes were observed during influenza infections, we strongly recommend seasonal vaccination.


  • Open Access

    Disorders of vesicular trafficking presenting with recurrent acute liver failure: NBAS, RINT1, and SCYL1 deficiency

    by Bianca Peters, Tal Dattner, Lea D. Schlieben, Tian Sun, Christian Staufner, Dominic Lenz

    Among genetic disorders of vesicular trafficking, there are three causing recurrent acute liver failure (RALF): NBAS, RINT1, and SCYL1‐associated disease. These three disorders are characterized by liver crises triggered by febrile infections and account for a relevant proportion of RALF causes. While the frequency and severity of liver crises in NBAS and RINT1‐associated disease decrease with age, patients with SCYL1 variants present with a progressive, cholestatic course. In all three diseases, there is a multisystemic, partially overlapping phenotype with variable expression, including liver, skeletal, and nervous systems, all organ systems with high secretory activity. There are no specific biomarkers for these diseases, and whole exome sequencing should be performed in patients with RALF of unknown etiology. NBAS, SCYL1, and RINT1 are involved in antegrade and retrograde vesicular trafficking. Pathomechanisms remain unclarified, but there is evidence of a decrease in concentration and stability of the protein primarily affected by the respective gene defect and its interaction partners, potentially causing impairment of vesicular transport. The impairment of protein secretion by compromised antegrade transport provides a possible explanation for different organ manifestations such as bone alteration due to lack of collagens or diabetes mellitus when insulin secretion is affected. Dysfunction of retrograde transport impairs membrane recycling and autophagy. The impairment of vesicular trafficking results in increased endoplasmic reticulum stress, which, in hepatocytes, can progress to hepatocytolysis. While there is no curative therapy, an early and consequent implementation of an emergency protocol seems crucial for optimal therapeutic management.